molecules of the month


oral BCL6 BTB inhibitor

promising in vitro safety + oral mouse/dog PK data

from virtual screen + SBDD

ACS Med. Chem. Lett., January 12, 2023

OICR, Toronto, CA (Janssen)

JNJ-65234637 chemical structure oral BCL6 BTB inhibitor - OICR, Toronto, CA (Janssen)
5 mins read

A protein-protein interaction inhibitor for a challenging-to-drug master transcription factor. OICR12694 is an oral protein-protein interaction inhibitor targeting the challenging-to-drug oncogenic transcription factor, B cell lymphoma 6 (BCL-6). As a master regulator of B cell differentiation in germinal centers and hence a common driver of B-cell malignancies like diffuse large B-cell lymphoma (DLBCL), BCL-6 inhibition could be beneficial for treatment of B-cell cancers and B-cell-mediated diseases. In 2015, JNJ signed a deal with Novera and the Ontario Institute for Cancer Research (OICR) to an exclusive worldwide license option for small molecules to treat blood cancers for up to $348M ($450M Canadian), in which the OICR will identify novel candidates from its drug discovery program and JNJ will be responsible for…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: